Liquidia Corporation (LQDA)
NASDAQ: LQDA · Real-Time Price · USD
23.58
+2.38 (11.23%)
Aug 12, 2025, 11:58 AM - Market open
Accolade Revenue
Liquidia had revenue of $3.12M in the quarter ending March 31, 2025, with 4.98% growth. This brings the company's revenue in the last twelve months to $14.14M, down -11.42% year-over-year. In the year 2024, Liquidia had annual revenue of $14.00M, down -19.97%.
Revenue (ttm)
$14.14M
Revenue Growth
-11.42%
P/S Ratio
121.64
Revenue / Employee
$83,200
Employees
170
Market Cap
2.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.00M | -3.49M | -19.97% |
| Dec 31, 2023 | 17.49M | 1.55M | 9.75% |
| Dec 31, 2022 | 15.94M | 3.08M | 23.98% |
| Dec 31, 2021 | 12.85M | 12.11M | 1,637.77% |
| Dec 31, 2020 | 739.63K | -7.33M | -90.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
LQDA News
- 5 hours ago - Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - What Next For Liquidia After Launch? - Seeking Alpha
- 7 weeks ago - Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™ - GlobeNewsWire
- 2 months ago - Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD - GlobeNewsWire
- 2 months ago - These Analysts Boost Their Forecasts On Liquidia - Benzinga
- 2 months ago - Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - GlobeNewsWire
- 3 months ago - Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - GlobeNewsWire